B+
Bull case
20%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
IMTX
ImmaticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+90.0
Score
AI commentary
News flow is sparse and social, options, short-interest and employee-sentiment data are unavailable; neutral numerical fields are placeholders, not evidence. The checked quote was modestly below the packet anchor, but no trusted source linked the move to earnings. The evidence base supports monitoring upcoming clinical and regulatory milestones rather than a high-conviction directional thesis.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-12eventUnconfirmed Q2 2026 earnings follow-upMedium impact
The packet schedules a T+3 post-earnings review for 2026-08-11, but the checked company IR and SEC pages did not provide a verifiable Q2 release, guidance update, transcript, or market-reaction explanation. Treat this as an evidence gap rather than a bullish signal.
2027-08-14catalystSUPRAME Phase 3 analyses and regulatory pathHigh impact
The company’s May 2026 release said interim and final SUPRAME analyses are expected to trigger in 2026, with BLA submission targeted for the first half of 2027 and commercial launch in the second half of 2027. [#PR-2026-05-12]
2027-08-14catalystMultiple 2026 clinical readoutsHigh impact
Immatics identified 2026 data milestones across anzu-cel, IMA203CD8, IMA402 and IMA401, including IMA402 monotherapy and combination data expected in the second half of 2026. [#PR-2026-05-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology